Motivating Occupational Virtual Experiences In Therapy for kids

项目摘要/摘要 简介：儿童治疗中的激励性职业虚拟体验(MOVE-IT)SBIR第二阶段 该计划将支持通过智能玩具为儿童偏瘫患者提供强化康复的远程医疗服务- 启用了激发高剂量、任务导向的上肢(UE)运动的游戏。虽然更高- 剂量训练几乎一致地与UE康复的更好结果有关[1]、[2]、[3]、[4]，实现 通过神经可塑性获得持久结果所需的重复是一项艰巨的挑战。这一举动- IT系统将采用结合虚拟和现实世界物理元素的治疗游戏，以提供一个转折点- 适合家庭和临床使用的关键解决方案。Move-IT将让患者参与重复的实践， 促进以证据为基础的方法，将已证实的概念整合到约束诱导的运动中 治疗(CIMT)和其他强化疗法[5]。这一创新的解决方案采用了多感官智能 玩具、先进的游戏引擎和低成本的运动跟踪，以创建促进持续遵守的游戏。 有待解决的问题：儿童偏瘫可由脑瘫(CP)或获得性脑损伤引起 (包括儿童中风、创伤、肿瘤或其他疾病)，并对必要的运动功能产生不利影响 自我照顾、游戏、探索性学习和其他日常活动[6]。现有系统目前不支持 远程保健提供改善UE功能所需的高剂量循证治疗。 长期目标：在远程指导和监测的支持下提供有效的家庭锻炼计划 儿童偏瘫的循证治疗。提高患者的参与度和对 强化治疗方案。降低成本，改善获得最先进康复服务的机会。提供 用于远程跟踪患者状态和进展的经过验证的指标。 第一阶段结果：第一阶段生产了一个智能玩具原型，两个UE治疗迷你游戏，人体运动学 跟踪软件和经过验证的UE电机性能指标。在芝加哥大学进行了一项初步研究。 弗吉尼亚(UVA)儿童医院涉及10名偏瘫儿童。分析确认了主要阶段I 假设Move-IT生成的指标与UE运动的黄金标准测量具有较高的标准效度 功能。患者/家长访谈/问卷调查有力地支持了该技术的接受度和可用性。 第二阶段总结：Move-IT第二阶段将生产一个商业系统，包括增强型智能玩具和 基于Quest的游戏软件，在整个治疗过程中持续参与；展示疗效； 建立安全性和可用性；并追求FDA的批准。第二阶段将最终以评分者盲目随机进行， 调查偏瘫儿童家庭使用效果的对照试验，通过金的变化来衡量- 与常规护理治疗(UCT)组相比，使用MOVE-IT的队列的UE功能的标准测量。 商业机会：商业化的高可能性得到Barron Associates过去的支持 在UE治疗的创新技术的开发、临床试验、FDA批准和营销方面取得成功。

PROJECT SUMMARY/ABSTRACT Introduction: The Motivating Occupational Virtual Experiences In Therapy for kids (MOVE-IT) SBIR Phase II program will support telehealth delivery of intensive rehabilitation for pediatric hemiplegia through smart toy- enabled games that inspire high-dosage, task-directed upper extremity (UE) movements. Although higher- dosage training is almost uniformly associated with better outcomes in UE rehabilitation [1], [2], [3], [4], achieving the repetitions necessary to attain lasting results through neuroplasticity is a formidable challenge. The MOVE- IT system will employ therapy games that combine virtual- and real-world physical elements to provide a turn- key solution suitable for both home and clinical use. MOVE-IT will engage patients in repetitive practice, facilitating an evidence-based approach that integrates proven concepts in constraint-induced movement therapy (CIMT) and other intensive therapy regimes [5]. This innovative solution employs a multi-sensory smart toy, advanced game engine, and low-cost motion tracking to create games that promote sustained adherence. Problem to be Addressed: Pediatric hemiplegia can result from Cerebral Palsy (CP) or acquired brain injury (including pediatric stroke, trauma, tumor, or other disease), and adversely affect motor functions essential to self-care, play, exploratory learning, and other daily activities [6]. Existing systems do not currently support telehealth delivery of the high-dosage, evidence-based therapy required for improvement in UE function. Long-Term Goals: Provide an effective home exercise program supported by remote guidance and monitoring of evidence-based treatment for pediatric hemiplegia. Improve patient participation and adherence to an intensive therapy regimen. Reduce the cost of, and improve access to, state-of-the-art rehabilitation. Provide validated metrics for remotely tracking patient status and progress. Phase I Results: Phase I produced a prototype smart toy, two UE therapy mini-games, human kinematics tracking software, and validated UE motor performance metrics. A pilot study was conducted at the University of Virginia (UVA) Children’s Hospital involving 10 children with hemiplegia. Analysis confirms the primary Phase I hypothesis that MOVE-IT generated metrics have high criterion validity with gold-standard measures of UE motor function. Patient/parent interviews/questionnaires strongly support the technology’s acceptance and usability. Phase II Summary: MOVE-IT Phase II will produce a commercial system including an enhanced smart toy and quest-based game software for sustained engagement over a full course of therapy; demonstrate efficacy; establish safety and usability; and pursue FDA-clearance. Phase II will culminate in a rater-blinded randomized, controlled trial to investigate efficacy in home use by children with hemiplegia, as measured by change in gold- standard measures of UE function for a cohort using MOVE-IT compared to a usual care treatment (UCT) group. Commercial Opportunity: High likelihood of commercialization is supported by Barron Associates’ past successes in development, clinical trials, FDA-clearance, and marketing of innovative technology for UE therapy.